Document:

Exhibit 10.10

MENLO THERAPEUTICS INC.

 

2019 EMPLOYEE SHARE PURCHASE PLAN

 

	1.	GENERAL; PURPOSE.

 

(a)           The
Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity
to purchase Shares. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee
Share Purchase Plan.

 

(b)           The
Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of new Employees
and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations.

 

(c)           On November 10, 2019, the Company entered into that certain Agreement and Plan of Merger
(the “Merger Agreement”) by and among the Company, Foamix Pharmaceuticals Ltd. (“Foamix”)
and Giants Merger Subsidiary, Ltd. (“Merger Sub”), pursuant to which Merger Sub merged with and into Foamix,
with Foamix continuing as the surviving corporation and a wholly-owned subsidiary of the Company (the “Merger”).
The Plan (formerly known as the Foamix Pharmaceuticals Ltd. 2019 Employee Share Purchase Plan) initially became effective upon
the approval of Foamix shareholders on April 10, 2019. The Plan was assumed by the Company pursuant to adoption by the Board effective
as of the consummation of the Merger (following the approval of Company shareholders on February 6, 2020) and the number
of Shares available for issuance under the Plan pursuant to Section 3 hereof has been adjusted based on the Exchange Ratio (as
defined in the Merger Agreement). On March 9, 2020, the Plan was amended by the Company
to reflect the consummation of the Merger.

 

	2.	Administration.

 

(a)           The
Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as
provided in Section 2(c).

 

(b)           The
Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:

 

(i)            To
determine how and when Purchase Rights will be granted and the provisions of each Offering (which need not be identical).

 

(ii)           To
designate from time to time which Related Corporations of the Company will be eligible to participate in the Plan.

 

(iii)          To
construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for its administration.
The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the
extent it deems necessary or expedient to make the Plan fully effective.

 

     

     

    

 

(iv)          To
settle all controversies regarding the Plan and Purchase Rights granted under the Plan.

 

(v)           To
suspend or terminate the Plan at any time as provided in Section 12.

 

(vi)          To
amend the Plan at any time as provided in Section 12.

 

(vii)         Generally,
to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of the Company
and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Share Purchase Plan.

 

(viii)        To
adopt such rules, procedures and sub-plans relating to the operation and administration of the Plan as are necessary or appropriate
under applicable local laws, regulations and procedures to permit or facilitate participation in the Plan by Employees who are
foreign nationals or employed or located outside the United States.

 

(c)           Subject
to the provisions of Applicable Law, the Board may delegate some or all of the administration of the Plan to a Committee or Committees.
If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the
powers theretofore possessed by the Board that have been delegated to the Committee (and references in this Plan to the Board
will thereafter be to the Committee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan,
as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with
the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. Whether or not the Board
has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy
and expediency that may arise in the administration of the Plan.

 

(d)           All
determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person
and will be final, binding and conclusive on all persons.

 

	3.	Shares subject to
the plan.

 

(a)           Subject
to the provisions of Section 11(a) relating to Capitalization Adjustments, the maximum number of Shares that may be issued under
the Plan following the Merger will not exceed 9,371,2581
Shares.

 

(b)           If
any Purchase Right granted under the Plan terminates without having been exercised in full, the Shares not purchased under such
Purchase Right will again become available for issuance under the Plan.

 

 

1
Reflects the conversion of the contingent stock rights at 1.8006 Menlo shares for each Foamix ordinary share.

 

    2

     

    

 

(c)           The
Shares purchasable under the Plan will be authorized but unissued or reacquired Shares, including Shares repurchased by the Company
on the open market.

 

	4.	Grant of purchase
rights; offering.

 

(a)           The
Board may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering (consisting
of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form
and will contain such terms and conditions as the Board will deem appropriate, and will comply with the requirement of Section
423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The terms and conditions
of an Offering shall be incorporated by reference into the Plan and treated as part of the Plan. The provisions of separate Offerings
need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference in the
document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed
27 months beginning with the Offering Date, and the substance of the provisions contained in Sections 5 through 8, inclusive.

 

(b)           If
a Participant has more than one Purchase Right outstanding under the Plan, unless he or she otherwise indicates in forms delivered
to the Company: (i) each form will apply to all of his or her Purchase Rights under the Plan, and (ii) a Purchase Right with a
lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) will
be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase
Right if different Purchase Rights have identical exercise prices) will be exercised.

 

(c)           The
Board will have the discretion to structure an Offering so that if the Fair Market Value of a Share on the first Trading Day of
a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a Share on the Offering Date for
that Offering, then (i) that Offering will terminate immediately as of that first Trading Day, and (ii) the Participants in such
terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period.

 

	5.	Eligibility.

 

(a)           Purchase
Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section 2(b), to Employees
of a Related Corporation. Except as provided in Section 5(b), an Employee will not be eligible to be granted Purchase Rights unless,
on the Offering Date, the Employee has been in the employ of the Company or the Related Corporation, as the case may be, for such
continuous period preceding such Offering Date as the Board may require, but in no event will the required period of continuous
employment be equal to or greater than two years. In addition, the Board may (unless prohibited by law) provide that no Employee
will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee’s customary employment
with the Company or the Related Corporation is more than 20 hours per week and more than five months per calendar year or such
other criteria as the Board may determine consistent with Section 423 of the Code. The Board may also exclude from participation
in the Plan or any Offering Employees who are “highly compensated employees” (within the meaning of Section 414(q)
of the Code) of the Company or a Related Corporation or a subset of such highly compensated employees.

 

    3

     

    

 

(b)           The
Board may provide that each person who, during the course of an Offering, first becomes an Eligible Employee will, on a date or
dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs
thereafter, receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of that
Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering,
as described herein, except that:

 

(i)            the
date on which such Purchase Right is granted will be the “Offering Date” of such Purchase Right for all purposes,
including determination of the exercise price of such Purchase Right;

 

(ii)           the
period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of
such Offering; and

 

(iii)          the
Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of the
Offering, he or she will not receive any Purchase Right under that Offering.

 

(c)           No Employee will be eligible for the grant of any Purchase Rights if, immediately after
any such Purchase Rights are granted, such Employee owns shares possessing five percent or more of the total combined voting power
or value of all classes of shares of the Company or of any Related Corporation. For purposes of this Section 5(c), the rules of
Section 424(d) of the Code will apply in determining the share ownership of any Employee, and shares which such Employee may purchase
under all outstanding Purchase Rights and options will be treated as shares owned by such Employee.

 

(d)           As
specified by Section 423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights only if such Purchase Rights,
together with any other rights granted under all Employee Share Purchase Plans of the Company and any Related Corporations, do
not permit such Eligible Employee’s rights to purchase shares of the Company or any Related Corporation to accrue at a rate
which, when aggregated, exceeds US $25,000 of Fair Market Value of such shares (determined at the time such rights are granted,
and which, with respect to the Plan, will be determined as of their respective Offering Dates) for each calendar year in which
such rights are outstanding at any time.

 

(e)           Officers
of the Company and any designated Related Corporation, if they are otherwise Eligible Employees, will be eligible to participate
in Offerings under the Plan. Notwithstanding the foregoing, the Board may (unless prohibited by law) provide in an Offering that
Employees who are highly compensated Employees within the meaning of Section 423(b)(4)(D) of the Code will not be eligible to
participate.

 

    4

     

    

 

	6.	Purchase Rights; Purchase
Price.

 

(a)           On
each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be granted a Purchase Right to purchase
up to that number of Shares purchasable either with a percentage or with a maximum dollar amount, as designated by the Board,
but in either case not exceeding 15% of such Employee’s earnings (as defined by the Board in each Offering) during the period
that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated
in the Offering, which date will be no later than the end of the Offering.

 

(b)           The
Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted for that Offering will be
exercised and Shares will be purchased in accordance with such Offering.

 

(c)           In
connection with each Offering made under the Plan, the Board may specify (i) a maximum number of Shares that may be purchased
by any Participant on any Purchase Date during such Offering, (ii) a maximum aggregate number of Shares that may be purchased
by all Participants pursuant to such Offering and/or (iii) a maximum aggregate number of Shares that may be purchased by all Participants
on any Purchase Date under the Offering. If the aggregate purchase of Shares issuable upon exercise of Purchase Rights granted
under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata
(based on each Participant’s accumulated Contributions) allocation of the Shares (rounded down to the nearest whole share)
available will be made in as nearly a uniform manner as will be practicable and equitable.

 

(d)           The
purchase price of Shares acquired pursuant to Purchase Rights will be not less than the lesser of:

 

(i)            an
amount equal to 85% of the Fair Market Value of the Shares on the Offering Date; or

 

(ii)           an
amount equal to 85% of the Fair Market Value of the Shares on the applicable Purchase Date.

 

	7.	Participation; Withdrawal;
Termination.

 

(a)           An
Eligible Employee may elect to participate in an Offering and authorize payroll deductions as the means of making Contributions
by completing and delivering to the Company, within the time specified in the Offering, an enrollment form provided by the Company.
The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified by the Board. Each Participant’s
Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general
funds of the Company except where applicable law or regulations requires that Contributions be deposited with a third party. If
permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering
Date (or, in the case of a payroll date that occurs after the end of the prior Offering but before the Offering Date of the next
new Offering, Contributions from such payroll will be included in the new Offering). If permitted in the Offering, a Participant
may thereafter reduce (including to zero) or increase his or her Contributions. If required under applicable law or regulations
or if specifically provided in the Offering, in addition to or instead of making Contributions by payroll deductions, a Participant
may make Contributions through the payment by cash, check or wire transfer prior to a Purchase Date.

 

    5

     

    

 

(b)           During
an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company a withdrawal
form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal,
such Participant’s Purchase Right in that Offering will immediately terminate and the Company will distribute as soon as
practicable to such Participant all of his or her accumulated but unused Contributions and such Participant’s Purchase Right
in that Offering shall thereupon terminate. A Participant’s withdrawal from that Offering will have no effect upon his or
her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment
form to participate in subsequent Offerings.

 

(c)           Unless
otherwise required by applicable law or regulations, Purchase Rights granted pursuant to any Offering under the Plan will terminate
immediately if the Participant either (i) is no longer an Employee for any reason or for no reason (subject to any post-employment
participation period required by law) or (ii) is otherwise no longer eligible to participate. The Company will distribute as soon
as practicable to such individual all of his or her accumulated but unused Contributions.

 

(d)           During
a Participant’s lifetime, Purchase Rights will be exercisable only by such Participant. Purchase Rights are not transferable
by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation
as described in Section 10.

 

(e)           Unless
otherwise specified in the Offering or required by applicable law or regulations, the Company will have no obligation to pay interest
on Contributions.

 

	8.	Exercise Of Purchase
Rights.

 

(a)           On
each Purchase Date, each Participant’s accumulated Contributions will be applied to the purchase of Shares, up to the maximum
number of Shares permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional
shares will be issued unless specifically provided for in the Offering.

 

(b)           Unless
otherwise provided in the Offering, if any amount of accumulated Contributions remains in a Participant’s account after
the purchase of Shares on the final Purchase Date of an Offering, then such remaining amount will not roll over to the next Offering
and will instead be distributed in full to such Participant after the final Purchase Date of such Offering without interest (unless
otherwise required by applicable law or regulations).

 

(c)           No
Purchase Rights may be exercised to any extent unless the Shares to be issued upon such exercise under the Plan are covered by
an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable
federal, state, foreign and other securities and other laws applicable to the Plan. If on a Purchase Date the Shares are not so
registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and the Purchase
Date will be delayed until the Shares are subject to such an effective registration statement and the Plan is in material compliance,
except that the Purchase Date will in no event be more than 27 months from the Offering Date. If, on the Purchase Date, as delayed
to the maximum extent permissible, the Shares are not registered and the Plan is not in material compliance with all applicable
laws and regulations, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to
the Participants without interest.

 

    6

     

    

 

	9.	Covenants Of The Company.

 

The Company will seek
to obtain from each federal, state, foreign or other regulatory commission or agency having jurisdiction over the Plan such authority
as may be required to grant Purchase Rights and issue and sell Shares thereunder unless the Company determines, in its sole discretion,
that doing so would cause the Company to incur costs that are unreasonable. If, after commercially reasonable efforts, the Company
is unable to obtain the authority that counsel for the Company deems necessary for the grant of Purchase Rights or the lawful issuance
and sale of Shares under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure
to grant Purchase Rights and/or to issue and sell Shares upon exercise of such Purchase Rights.

 

	10.	Designation of Beneficiary.

 

(a)           The
Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any Shares
and/or Contributions from the Participant’s account under the Plan if the Participant dies before such shares and/or Contributions
are delivered to the Participant. The Company may, but is not obligated to, permit the Participant to change such designation
of beneficiary. Any such designation and/or change must be on a form approved by the Company.

 

(b)           If
a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any Shares and/or Contributions
to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to the
knowledge of the Company), the Company, in its sole discretion, may deliver such Shares and/or Contributions, without interest,
to the Participant’s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then
to such other person as the Company may designate.

 

	11.	Adjustments Upon Changes
In Shares; Corporate Transactions.

 

(a)           In
the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum
number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities by which
the share reserve is to increase automatically each year pursuant to Section 3(a), (iii) the class(es) and number of securities
subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and (iv) the class(es) and number
of securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments,
and its determination will be final, binding and conclusive.

 

(b)           In
the event of a Corporate Transaction, then: (i) any surviving corporation or acquiring corporation (or the surviving or acquiring
corporation’s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including
a right to acquire the same consideration paid to the shareholders in the Corporate Transaction) for outstanding Purchase Rights,
or (ii) if any surviving or acquiring corporation (or its parent company) does not assume or continue such Purchase Rights or
does not substitute similar rights for such Purchase Rights, then the Participants’ accumulated Contributions will be used
to purchase Shares (rounded down to the nearest whole share) within ten business days prior to the Corporate Transaction under
the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase.

 

    7

     

    

 

	12.	Amendment, Termination
Or Suspension Of The Plan.

 

(a)           The
Board may amend the Plan at any time in any respect the Board deems necessary or advisable. However, except as provided in Section
11(a) relating to Capitalization Adjustments, shareholder approval will be required for any amendment of the Plan for which shareholder
approval is required by applicable law, regulations or listing requirements.

 

(b)           The
Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan while the Plan is suspended
or after it is terminated.

 

(c)           Any
benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted before an amendment, suspension
or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i) with the
consent of the person to whom such Purchase Rights were granted, (ii) as necessary to comply with any laws, listing requirements,
or governmental regulations (including, without limitation, the provisions of Section 423 of the Code and the regulations and
other interpretive guidance issued thereunder relating to Employee Share Purchase Plans) including without limitation any such
regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii) as necessary
to obtain or maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights
without a Participant’s consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies
with the requirements of Section 423 of the Code.

 

	13.	Effective Date Of
Plan.

 

The Plan initially
became effective upon the approval of Foamix shareholders on April 10, 2019, and was assumed by the Company pursuant to adoption
by the Board effective as of the consummation of the Merger (following the approval of Company shareholders on February 6, 2020).

 

	14.	Miscellaneous provisions.

 

(a)           Proceeds
from the sale of Shares pursuant to Purchase Rights will constitute general funds of the Company.

 

(b)           A
Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, Shares subject to
Purchase Rights unless and until the Participant’s Shares acquired upon exercise of Purchase Rights are recorded in the
books of the Company (or its transfer agent).

 

(c)           The
Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the at
will nature of a Participant’s employment, if applicable, or be deemed to create in any way whatsoever any obligation on
the part of any Participant to continue in the employ of the Company or a Related Corporation, or on the part of the Company or
a Related Corporation to continue the employment of a Participant.

 

    8

     

    

 

(d)           The
provisions of the Plan will be governed by the laws of the State of Delaware without resort to that state’s conflicts of
laws rules.

 

(e)           If
any particular provision of the Plan is found to be invalid or otherwise unenforceable, such provision will not affect the other
provisions of the Plan, but the Plan will be construed in all respects as if such invalid provision were omitted.

 

(f)            If
any provision of the Plan does not comply with applicable law or regulations, such provision shall be construed in such a manner
as to comply with applicable law or regulations.

 

	15.	Definitions.

 

As used in the Plan,
the following definitions will apply to the capitalized terms indicated below:

 

(a)           “Applicable
Law” means the legal requirements applicable to the administration of equity incentive plans, any applicable laws, rules
and regulations in Israel and in any country or jurisdiction where Awards are granted under the Plan, as such laws, rules, regulations
and requirements shall be in place from time to time including any Stock Exchange rules or regulations;

 

(b)           “Board”
means the Board of Directors of the Company.

 

(c)           “Capitalization
Adjustment” means any change that is made in, or other events that occur with respect to, the Shares subject to the
Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by
the Company through merger, consolidation, reorganization, recapitalization, reincorporation, share dividend, dividend in property
other than cash, large nonrecurring cash dividend, share split, liquidating dividend, combination of shares, exchange of shares,
change in corporate structure or other similar equity restructuring transaction, as that term is used in Financial Accounting
Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion
of any convertible securities of the Company will not be treated as a Capitalization Adjustment.

 

(d)           “Code”
means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.

 

(e)           “Committee”
means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section
2(c).

 

(f)            “Company”
means Menlo Therapeutics Inc. a Delaware corporation.

 

(g)           “Contributions”
means the payroll deductions and other additional payments specifically provided for in the Offering that a Participant contributes
to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided
for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering
through payroll deductions.

 

    9

     

    

 

(h)           “Corporate Transaction” means the consummation, in a single transaction
or in a series of related transactions, of any one or more of the following events:

 

(i)            a
sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated
assets of the Company and its Subsidiaries;

 

(ii)           a
sale or other disposition of more than 50% of the outstanding securities of the Company;

 

(iii)          a
merger, consolidation or similar transaction following which the Company is not the surviving corporation; or

 

(iv)          a
merger, consolidation or similar transaction following which the Company is the surviving corporation but the Shares outstanding
immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation
or similar transaction into other property, whether in the form of securities, cash or otherwise.

 

(i)            “Director”
means a member of the Board.

 

(j)            “Eligible
Employee” means an Employee who meets the requirements set forth in the document(s) governing the Offering for eligibility
to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth
in the Plan.

 

(k)           “Employee”
means any person, including an Officer or Director, who is “employed” for purposes of Section 423(b)(4) of the Code
by the Company or a Related Corporation. However, service solely as a Director, or payment of a fee for such services, will not
cause a Director to be considered an “Employee” for purposes of the Plan.

 

(l)            “Employee
Share Purchase Plan” means a plan that grants Purchase Rights intended to be options issued under an “employee
share purchase plan,” as that term is defined in Section 423(b) of the Code.

 

(m)          “Exchange
Act” means the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder.

 

(n)           “Fair
Market Value” means, as of any date, the value of the Shares determined as follows:

 

(i)            If
the Shares are listed on any established share exchange or traded on any established market, the Fair Market Value of a Share
will be the closing sales price for such shares as quoted on such exchange or market (or the exchange or market with the greatest
volume of trading in the Shares) on the date of determination, as reported in such source as the Board deems reliable. Unless
otherwise provided by the Board, if there is no closing sales price for the Shares on the date of determination, then the Fair
Market Value will be the closing sales price on the last preceding date for which such quotation exists.

 

    10

     

    

 

(ii)           In
the absence of such markets for the Shares, the Fair Market Value will be determined by the Board in good faith in compliance
with applicable laws and regulations and in a manner that complies with Sections 409A of the Code.

 

(o)           “Offering”
means the grant to Eligible Employees of Purchase Rights, with the exercise of those Purchase Rights automatically occurring at
the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the “Offering
Document” approved by the Board for that Offering.

 

(p)           “Offering
Date” means a date selected by the Board for an Offering to commence.

 

(q)           “Officer”
means a person who is an officer of the Company or a Related Corporation within the meaning of Section 16 of the Exchange Act.

 

(r)            “Participant”
means an Eligible Employee who holds an outstanding Purchase Right.

 

(s)           “Plan”
means this Menlo Therapeutics Inc. 2019 Employee Share Purchase Plan.

 

(t)            “Purchase
Date” means one or more dates during an Offering selected by the Board on which Purchase Rights will be exercised and
on which purchases of Shares will be carried out in accordance with such Offering.

 

(u)           “Purchase
Period” means a period of time specified within an Offering, generally beginning on the Offering Date or on the first
Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods.

 

(v)           “Purchase
Right” means an option to purchase Shares granted pursuant to the Plan.

 

(w)          “Related
Corporation” means any “parent corporation” or “subsidiary corporation” of the Company whether
now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code.

 

(x)           “Securities
Act” means the Securities Act of 1933, as amended.

 

(y)           “Share”
means a share of common stock of the Company.

 

(z)           “Trading
Day” means any day on which the exchange(s) or market(s) on which Shares are listed, including but not limited to the
NYSE, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for
trading.

 

    11

     

    

 

MENLO THERAPEUTICS INC.

 

2019 EMPLOYEE SHARE PURCHASE PLAN

 

SUB-PLAN FOR ISRAELI PARTICIPANTS

 

	1.	GENERAL

 

(a)           This
sub-plan (the “Sub-Plan”) shall apply only to Eligible Employees who are residents of the State of Israel upon
the Purchase Date (collectively, “Israeli Eligible Employees”). The provisions specified hereunder shall form
an integral part of the Menlo Therapeutics Inc. 2019 Employee Share Purchase Plan (hereinafter the “Plan”).

 

(b)           This
Sub-Plan is adopted pursuant to the authority of the Board under section 2(b)(viii) of the Plan. This Sub-Plan is to be read as
a continuation of the Plan and modifies Purchase Rights granted to Israeli Eligible Employees only to the extent necessary to
comply with the requirements set by the Israeli law in general, and in particular, with the provisions of the Israeli Income Tax
Ordinance [New Version] 1961, as may be amended or replaced from time to time and in order to comply with any approval or ruling
received by the Company in relation thereof. This Sub-Plan does not add to or modify the Plan in respect of any other category
of Eligible Employees.

 

(c)           The
purpose of this Sub-plan is to provide a method whereby Israeli Eligible Employees may be offered an opportunity to purchase Shares
that qualify for favorable tax treatment under Section 102 of the Ordinance, as defined in Section 2.

 

(d)           The
Plan and this Sub-Plan are complimentary to each other and shall be deemed as one. In the event of any conflict, whether explicit
or implied, between the provisions of this Sub-Plan and the Plan, the provisions set out in the Sub-Plan shall prevail.

 

(e)           Any
capitalized term not specifically defined in this Sub-Plan shall be construed according to the interpretation given to it in the
Plan.

 

	2.	DEFINITIONS

 

(a)           “102 Purchase Right” means any Purchase Right issued to an Approved
Israeli Eligible Employee pursuant to Section 102 of the Ordinance.

 

(b)           “Approved Israeli Eligible Employee” means an Israeli Eligible Employee
who is not a Controlling Share Holder of the Company.

 

(c)           “Capital Gain Purchase Right” or “CGA” means a Trustee
102 Purchase Right elected and designated by the Company to qualify under the capital gain tax treatment in accordance with the
provisions of Section 102(b)(2) of the Ordinance.

 

    12

     

    

 

(d)           “Controlling Share Holder” shall have the meaning ascribed to it in
Section 32(9) of the Ordinance.

 

(e)           “ITA” means the Israeli Tax Authority.

 

(f)            “Israeli Purchase Right Agreement” means the enrollment form completed
by the Israeli Eligible Employee electing to participate in the Plan and receive Purchase Rights.

 

(g)           “Non-Trustee 102 Purchase Right” means a 102 Purchase Right granted
pursuant to Section 102(c) of the Ordinance and not held in trust by a Trustee.

 

(h)           “Ordinary Income Purchase Right” or “OIA” means a
Trustee 102 Purchase Right elected and designated by the Company to qualify under the ordinary income tax treatment in accordance
with the provisions of Section 102(b)(1) of the Ordinance.

 

(i)            “Ordinance” means the Israeli Income Tax Ordinance [New Version] –
1961, as now in effect or as hereafter amended.

 

(j)            “Section 102” means Section 102 of the Ordinance and any regulations,
rules, orders or procedures promulgated thereunder as now in effect or as hereafter amended.

 

(k)           “Tax” means any applicable tax and other compulsory payments such as
social security and health tax contributions under any applicable law.

 

(l)             “Trustee” means any person or entity appointed by the Company to serve
as a trustee and approved by the ITA, all in accordance with the provisions of Section 102(a) of the Ordinance, as may be replaced
from time to time.

 

(m)          “Trustee 102 Purchase Right” means a 102 Purchase Right granted to an
Approved Israeli Eligible Employee pursuant to Section 102(b) of the Ordinance and held in trust by a Trustee for the benefit
of an Approved Israeli Eligible Employee.

 

(n)           “Unapproved Israeli Eligible Employee” means an Israeli Eligible Employee
who is a Controlling Share Holder of the Company.

 

	3.	ISSUANCE OF PURCHASE RIGHTS

 

(a)           The
Company may designate Purchase Rights granted to Approved Israeli Eligible Employees pursuant to Section 102 as Trustee 102 Purchase
Rights or Non-Trustee 102 Purchase Rights.

 

(b)           The
grant of Trustee 102 Purchase Rights shall be subject to this Sub-Plan and shall not become effective prior to the lapse of 30
days from the date the Plan has been submitted for approval by the ITA and shall be conditioned upon the approval of the Plan
and this Sub-Plan by the ITA and the provisions of the tax ruling received in relation to the Plan.

 

(c)           Trustee
102 Purchase Rights may either be classified as Capital Gain Purchase Rights (CGAs) or Ordinary Income Purchase Rights (OIAs).

 

    13

     

    

 

(d)           No
Trustee 102 Purchase Right may be granted under this Sub-Plan to any Approved Israeli Eligible Employee, unless and until the
Company has filed with the ITA its election regarding the type of Trustee 102 Purchase Rights, whether CGAs or OIAs, that will
be granted under the Plan and this Sub-Plan (the “Election”). Such Election shall become effective beginning
the first date of grant of a Trustee 102 Purchase Right under this Sub-Plan and shall remain in effect at least until the end
of the year following the year during which the Company first granted Trustee 102 Purchase Rights. The Election shall obligate
the Company to grant only the type of Trustee 102 Purchase Right it has elected, and shall apply to all Israeli Eligible Employees
who are granted Trustee 102 Purchase Rights during the period indicated herein, all in accordance with the provisions of Section
102(g) of the Ordinance. For the avoidance of doubt, the Election shall not prevent the Company from granting Non-Trustee 102
Purchase Rights simultaneously.

 

(e)           All
Trustee 102 Purchase Rights must be held in trust by the Trustee, as described in Section 4 below.

 

(f)            Any
Trustee 102 Purchase Rights shall be subject to any tax ruling received by the Company or any Employing Company in relation to
the Plan and the Sub-plan (“Tax Ruling”).

 

(g)           The
designation of Non-Trustee 102 Purchase Rights and Trustee 102 Purchase Rights shall be subject to the terms and conditions set
forth in Section 102 and the Tax Ruling.

 

(h)           Purchase
Rights granted to Unapproved Israeli Eligible Employees shall be subject to tax according to the provisions of the Ordinance and
shall not be subject to the Trustee arrangement detailed herein.

 

	4.	TRUSTEE

 

(a)            Trustee
102 Purchase Rights which shall be granted under this Sub-Plan and/or any Share issued upon exercise of a Trustee 102 Purchase
Right and/or other Shares received following any realization of rights under the Plan, shall be allocated or issued to the Trustee
for the benefit of the Approved Israeli Eligible Employees, in accordance with the provisions of Section 102. In the event that
the requirements for Trustee 102 Purchase Rights are not met, the Trustee 102 Purchase Rights may be regarded as Non-Trustee 102
Purchase Rights or as Purchase Rights which are not subject to Section 102, all in accordance with the provisions of Section 102.

 

(b)           With
respect to any Trustee 102 Purchase Right, subject to the provisions of Section 102, an Approved Israeli Eligible Employee shall
not sell or release from trust any Share received upon the exercise of a Trustee 102 Purchase Right and/or any Share received
following any realization of rights, including, without limitation, stock dividends, under the Plan at least until the lapse of
the period of time required under Section 102 or any shorter period of time determined by the ITA (the “Holding Period”).
Notwithstanding the above, if any such sale or release occurs during the Holding Period, the sanctions under Section 102 shall
apply to and shall be borne by such Approved Israeli Eligible Employee. In the event a stock dividend is declared and/or other
rights are granted with respect to Shares issued upon exercise of Trustee 102 Stock Purchase Rights, such stock dividend and/or
other rights shall also be deposited with the Trustee and will be subject to the provisions of this Section 4. The Holding Period
for Shares and/or rights shall be measured from the commencement of the Holding Period for the Trustee 102 Stock Purchase Rights
and Share with respect to which the stock dividend was declared and/or other rights were granted

 

    14

     

    

 

(c)           In
the event a cash dividend is paid on the Shares, the Trustee shall transfer the dividend proceeds to the Approved Israeli Eligible
Employee after deduction of taxes and mandatory payments in compliance with applicable withholding requirements, and subject to
any other requirements imposed by the ITA.

 

(d)           Notwithstanding
anything to the contrary, the Trustee shall not release or sell any Shares allocated or issued upon exercise of a Trustee 102
Purchase Right unless the Company and the Trustee are satisfied that the full amounts of Tax due have been paid or will be paid.

 

(e)           Upon
receipt of any Trustee 102 Purchase Right, the Approved Israeli Eligible Employee will consent to the grant of the Purchase Right
under Section 102 and undertake to comply with the terms of Section 102 and the trust arrangement between the Company and the
Trustee.

 

	5.	THE PURCHASE RIGHTS

 

Purchase Rights which
are Trustee 102 Purchase Rights will not be satisfied using reacquired shares unless approved by the ITA.

 

	6.	ASSIGNABILITY, DESIGNATION AND SALE OF PURCHASE RIGHTS

 

(a)           In
addition to section 7(d) of the Plan no Purchase Right or any right with respect thereto, or purchasable hereunder, whether fully
paid or not, shall be assignable, transferable or given as collateral, or any right with respect to any Purchase Right given to
any third party whatsoever, and during the lifetime of the Israeli Eligible Employee, each and all of such Israeli Eligible Employee’s
rights with respect to an Purchase Right shall belong only to the Israeli Eligible Employee. Any such action made directly or
indirectly, for an immediate or future validation, shall be void.

 

(b)           As
long as Purchase Rights or Shares issued or purchased hereunder are held by the Trustee on behalf of the Israeli Eligible Employee,
all rights of the Israeli Eligible Employee over the Shares cannot be transferred, assigned, pledged or mortgaged, other than
by will or laws of descent and distribution.

 

	7.	INTEGRATION OF SECTION 102 AND APPROVALS FROM THE ITA

 

(a)           With
regard to Trustee 102 Purchase Rights, the provisions of the Plan and/or the Sub-Plan and/or the Israeli Purchase Right Agreement
shall be subject to the provisions of Section 102, the Tax Ruling and any approval issued by the ITA and the said provisions shall
be deemed an integral part of the Plan, the Sub-Plan and the Israeli Purchase Right Agreement.

 

    15

     

    

 

(b)           Any
provision of Section 102 and/or the Tax Ruling and/or any approval issued by the ITA which must be complied with in order to receive
and/or to maintain any tax benefit pursuant to Section 102, which is not expressly specified in the Plan, the Sub-Plan or the
Israeli Purchase Right Agreement, shall be considered binding upon the Company and the Israeli Eligible Employees.

 

	8.	TAX CONSEQUENCES

 

(a)           Any
tax consequences arising from the grant, exercise, or sale of any Purchase Right or Shares or from any other event or act (of
the Company, and/or its Related Corporations, and the Trustee or the Israeli Eligible Employee), hereunder, shall be borne solely
by the Israeli Eligible Employee. The Company and/or its Related Corporations, and/or the Trustee shall withhold Tax according
to the requirements under the applicable laws, rules, and regulations, including withholding taxes at source. Furthermore, the
Israeli Eligible Employee agrees to indemnify the Company and/or its Related Corporations and/or the Trustee and hold them harmless
against and from any and all liability for any such Tax or interest or penalty thereon, including without limitation, liabilities
relating to the necessity to withhold, or to have withheld, any such Tax from any payment made to the Israeli Eligible Employee.
All taxes shall be in accordance with the Tax Ruling.

 

(b)           The
Company and/or, when applicable, the Trustee shall not be required to release any Share to an Israeli Eligible Employee until
all required Tax payments have been fully made.

 

(c)           Approved
Purchase Rights and any applicable Shares that do not comply with the requirements of Section 102 and the Tax Ruling shall be
considered Non-Approved 102 Purchase Rights or Purchase Rights subject to tax under Section 3(i) or 2 of the Ordinance.

 

(d)           With
respect to Non-Trustee 102 Purchase Rights, if the Israeli Eligible Employee ceases to be employed by the Company or any Related
Corporation, or otherwise if so requested by the Company or the Related Corporation, the Israeli Eligible Employee shall extend
to the Company and/or the Related Corporation a security or guarantee for the payment of Tax due at the time of sale of Shares,
in accordance with the provisions of Section 102.

 

(e)           Should
any provision in the Plan and/or Sub-Plan disqualify the Plan and/or Sub-Plan and/or the Purchase Rights granted thereunder from
beneficial tax treatment pursuant to the provisions of Section 102, such provision shall be considered invalid either permanently
or until the ITA provides approval of compliance with Section 102.

 

	9.	ONE TIME BENEFIT

 

(a)           The
Purchase Rights and underlying Shares are extraordinary, one-time benefit granted to the Eligible Employees, and are not and shall
not be deemed a salary component for any purpose whatsoever, including in connection with calculating severance compensation under
applicable law.

 

    16Exhibit 10.13

March 25, 2020

David Domzalski

520 U.S. Highway 22, Suite 204

Bridgewater, NJ 08807

 

Dear David,

 

This letter agreement (the “Agreement”)
contains the terms and conditions of your employment with Foamix Pharmaceuticals Inc. (the “Company”), a subsidiary
of Menlo Therapeutics Inc. (“Menlo”), effective as of March 9, 2020 the (the “Effective Date”).
Unless stated otherwise below, this Agreement will supersede your previous employment agreement with the Company, dated November
27, 2017 (the “Previous Employment Agreement”). You may be interchangeably referred to as “you”
or “the Executive” within this Agreement. Additionally, where the context permits, references to “the Company”
shall include the Company, its subsidiaries and affiliates and any successor thereto. The terms and conditions of this Agreement
are as follows:

 

1.                 
Term of Employment. The Executive’s employment with the Company commenced as of the Effective Date. The terms
and conditions of this Agreement shall be effective as of the Effective Date and will, unless earlier terminated in accordance
with the terms and conditions of Section 8 of this Agreement, continue for an unfixed period. The period during which the Executive
is employed under this Agreement is referred to as the “Employment Term.”

 

2.                 
Position and Reporting. During the Employment Term, the Executive will serve in the position of CEO of Menlo and
will report directly to Menlo’s Board of Directors (the “Board”). The Executive will also be required
to communicate regularly with other management and team members as needed in the performance of his duties hereunder.

 

3.                 
Duties and Responsibilities. During the Employment Term, the Executive (i) agrees to render full-time services in
performing his duties and responsibilities to the Company and its subsidiaries and affiliates (including Menlo) and will have no
other employment and no other business ventures which are undisclosed to the Company or which conflict with his duties under this
Agreement and (ii) will have such duties, commensurate with his position, as are assigned to him by the Board from time to time,
which duties will include, inter alia, the duties and responsibilities set forth on Exhibit A hereto, subject in
each case to the power of the Board to expand or limit such duties and responsibilities.

 

     

     

    

 

4.                 
Compensation and Benefits.

 

(a)          
Base Salary. The Executive will receive an annual base salary equal to US$616,000, payable in accordance with the
Company’s normal payroll practices as in effect from time to time (the “Base Salary”). Such Base Salary
shall be reviewed at least annually by the Board or by the Compensation Committee of the Board (the “Committee”),
and may be increased in the sole discretions of the Committee, but not decreased.

 

(b)          
Cash Incentive Compensation. The Executive will be eligible to receive additional cash incentive compensation during
the Employment Term as follows:

 

(i)                
In respect of each fiscal year during the Employment Term, the Executive will have the opportunity to earn cash incentive
compensation equal to 60% of the Base Salary as in effect on the last day of such period (the “Target Bonus”),
up to the maximum bonus opportunity allowable under the applicable annual bonus plan or program in effect from time to time (such
maximum bonus opportunity currently being 200% of the Target Bonus), subject to the achievement of both personal and company performance
criteria determined by the Board or the Committee, in accordance with the terms of the applicable annual bonus plan or program
as shall be in effect from time to time.

 

(ii)              
Any payment to be made under this Section 4 will only be paid to the Executive if he is actively employed by the Company
or an affiliate on the payment date; however, without derogating from the generality of the above, where the Executive was
employed only part of a year, the Board has full discretion to resolve that any payment under this Section 4 (if any) may be pro-rated
in accordance with the portion of the year in which the Executive had been actually employed.

 

(c)           
Equity Incentive Grants. During the Employment Term, the Executive shall be eligible to receive equity-based compensation
to be awarded, at the sole discretion of the Committee (and at a level commensurate with the Executive’s position as CEO,
as compared to other senior executives of the Company and its affiliates), which may be subject to the achievement of performance
targets set by the Committee. All equity-based awards shall be subject to the terms and conditions set forth in the applicable
plan and award agreements, and in all cases shall be as determined by the Committee.

 

(d)          
Reimbursement of Expenses. Consistent with its policies as established from time to time, the Company will reimburse
the Executive for all business expenses that he reasonably incurs in connection with the performance of his duties hereunder during
the Employment Term, as substantiated by appropriate documentation. All such expenses will either be paid directly by the Company
or under an expense account arrangement approved and implemented by the Company.

 

(e)          
Paid Time Off.

 

(i)                
The Executive will be entitled to a total of 25 business days of paid vacation and sick days per calendar year during the
Employment Term (pro-rated for any partial year) in accordance with the Company’s vacation policy as in effect from time
to time. Vacation and sick days accrue ratably over the calendar year at the rate of 1.66 days per month and accrued but unused
vacation and sick days may be carried over to the next year up to a cap of 5 days.

 

    2

     

    

 

(ii)             
The Executive will be entitled to additional paid time-off in respect of federal holidays in accordance with the Company’s
policies as in effect from time to time.

 

(f)           
Employee Benefits. During the Employment Term, the Executive and his eligible dependents will be entitled to participate
in the Company’s healthcare plan as in effect from time to time (the “Healthcare Plan”) on the same terms
as other senior executives of the Company and its affiliates; provided that if no such plan in which the Executive is eligible
to participate is in effect at any time during the Employment Term, the Company will reimburse the Executive for any monthly premiums
that the Executive pays in securing healthcare coverage for himself and his dependents during the Employment Term, up to a maximum
of $4200 per month (the “Healthcare Reimbursement”). All matters of eligibility under the Company’s plans
will be determined solely by the carriers providing such insurance.

 

5.                 
Prior Engagement. The Executive hereby represents and warrants that he has received from the Company and its subsidiaries
and affiliates, as applicable, all and any payments and benefits due to him with respect to his employment under the Previous Employment
Agreement and its termination. Notwithstanding the above, the Executive acknowledges that the commencement date for the calculation
of his seniority in the Company and its subsidiaries and affiliates, for the purpose of all rights and benefits owed to him under
law and this Agreement, shall commence as of April 14, 2014 and that the terms and conditions of the Executive’s employment
with the Company are exclusively and in all respects settled and determined under this Agreement.

 

6.                 
Restrictive Covenants.

 

(a)          
Non-Competition. The Executive recognizes that, in the event his employment with the Company is terminated for any
reason, whether voluntarily or involuntarily, his knowledge of the Confidential Information (as defined below) and trade secrets
of the Company and its subsidiaries and affiliates and his role in the Company and its business may allow him to compete or to
assist a third party to compete unfairly with the Company or its subsidiaries or affiliates. The Executive shall not, in any manner
whatsoever, directly or indirectly, anywhere in the world where the Company conducts its business, both during his employment hereunder
and for 12 months following the termination of his employment with the Company for any reason (the “Restricted Period”),
(i) form, carry on, engage in or be concerned with or interested in (financially or in any other capacity); (ii) advise, lend money
to, guarantee the debts or obligations of or permit the Executive’s name or any part thereof to be used in the promotion
or advancement of; or (iii) be employed by or render any services (as an employee, independent contractor, consultant, or otherwise)
to, any individual or other entity engaged in, or concerned with or interested in, any business that develops or commercializes
foam or topical tetracycline antibiotics or is otherwise directly competitive with, the business of the Company and its subsidiaries
and affiliates (i.e., any compound that is the same or substantially similar to a compound being developed or sold by the Company
or any of its subsidiaries or affiliates) (each, a “Competitive Business”), in each case without the prior written
consent of the Company.

 

    3

     

    

 

(b)          
Non-Solicitation. The Executive will not, in any manner whatsoever, directly or indirectly, without the prior written
consent of the Company, at any time during the Restricted Period:

 

(i)                
induce or endeavor to induce (A) any employee of the Company or any of its affiliates to leave employment with the Company
or any subsidiary or affiliate or (B) any consultant or contractor of the Company or any of its subsidiaries or affiliates to terminate
its relationship as such with the Company or any such subsidiary or affiliate during any period of time that the business services
provided, directly or indirectly, by such consultant or contractor are exclusively or primarily being provided to the Company and
its subsidiaries or affiliates, provided, that this clause (i) shall not preclude customary non-targeted recruiting efforts or
general solicitations that are not specifically directed to, but which may have the effect of causing an employee, consultant or
contractor to leave the employment or arrangement with the Company or any subsidiary or affiliate;

 

(ii)              
employ or attempt to employ or assist any individual or other entity to employ any employee of the Company or any subsidiary
or affiliate or to retain any consultant or contractor during any period of time that the business services provided, directly
or indirectly, by such consultant or contractor are exclusively or primarily being provided to the Company or any subsidiary or
affiliate, provided, that this clause (ii) shall not preclude an employer of the Executive from offering employment or consulting
or contracting services to anyone without the direct or indirect assistance of the Executive; or

 

(iii)             
for the purpose of competing with the Company or any of its subsidiaries, solicit, endeavor to solicit or otherwise interfere
with the relationship of the Company or any subsidiary or affiliate with, any individual or other entity that: (A) is a customer
or supplier of the Company or any subsidiary or affiliate at the date hereof and/or at the date of any termination of the Executive’s
employment, (B) was a major customer or supplier of the Company or any subsidiary or affiliate at any time within 24 months prior
to the date of any termination of the Executive’s employment; or (C) has been pursued as a prospective major customer or
supplier by or on behalf of the Company or any subsidiary or affiliate at any time within 12 months prior to the date of any termination
of the Executive’s employment, and in respect of whom the Company or any subsidiary or affiliate has not determined to cease
all such pursuit.

 

    4

     

    

 

 

(c)          
Confidentiality. The Executive acknowledges that by reason of the Executive’s employment with the Company,
he will have access to Confidential Information and trade secrets of the Company and its subsidiaries and affiliates, and that
such Confidential Information and trade secrets are essential components of the business of the Company and its subsidiaries and
affiliates, and are proprietary and would be of great value and benefit to competitors of the Company and its subsidiaries and
affiliates. “Confidential Information” includes anything respecting the Company and its subsidiaries and affiliates
or their respective businesses or operations, and which is not made readily available to the general public including, but not
limited to: (a) the identities, contact information, buying habits or practices of any of the Company’s customers; (b) the
Company’s advertising and marketing strategies, methods, research and related data; (c) the names of any of the Company’s
vendors or suppliers; (d) the cost, type and quantity of materials and/or supplies ordered by the Company; (e) the prices at which
the Company obtains or has obtained or sells or has sold its products or services; (f) the Company’s costs, methods and
objectives (including those methods licensed from other entities); (g) any technical information owned or created by the Company
or licensed from another entity; (h) any inventions, techniques or proprietary methods; (i) any pending or issued patents; (j)
financial or tax records; (k) personal information belonging to the Company’s current or former employees, owners and/or
customers unrelated to terms or conditions of employment (including, but not limited to, Social Security numbers, birthdates,
home addresses and telephone numbers, banking or credit card information, and medical information) (l) any “trade secrets”
as such term is defined in the Uniform Trade Secrets Act, Defend Trade Secrets Act, New Jersey Trade Secrets Act and applicable
common law or any other Confidential Information of, about, or concerning the business of the Company; and/or (m) such other Confidential
Information or data of any kind, nature, or description as may be designated as “Confidential” from time to time by
the Company. The Executive agrees that both during and after his employment with the Company, he will not disclose to any individual
or other entity, except in the proper course of his employment, or use for his own purposes or for purposes other than those of
the Company or its subsidiaries and affiliates, any Confidential Information or trade secrets of the Company or its subsidiaries
or affiliates, acquired by the Executive. If information enters the public domain, except as a result of a breach of this Section
6(c) by the Executive or a breach of another confidentiality agreement to which the Company or any subsidiary or affiliate is
a party, the information will not be deemed Confidential Information or a trade secret protected by this Section 6(c). If the
Executive is compelled by law to disclose Confidential Information or trade secrets of the Company or its subsidiaries and affiliates,
pursuant to subpoena, an order from a court of competent jurisdiction, or other applicable legal authority, the Executive may
disclose such Confidential Information or trade secrets to the extent so required, but will, if possible, (i) provide reasonable
advance notice of the subpoena, court order, or legal authority to the Company, and (ii) afford the Company the reasonable opportunity
to take legal action to contest, challenge, narrow or otherwise limit or condition the disclosure.

 

(d)           Exceptions.
Nothing in this Agreement prohibits Employee from reporting an event that he reasonably and in good faith believes is a
violation of law to the relevant law-enforcement agency including but not limited to the Department of Justice, the
Securities and Exchange Commission, the Congress, and any agency Inspector General, or from cooperating in an investigation
conducted by such a government agency. This may include disclosure of trade secret or confidential information within the
limitations permitted by the Defend Trade Secrets Act (“DTSA”). Under the DTSA, no individual will be held
criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret of the Company
that is: (A) made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to
an attorney, and (ii) made solely for the purpose of reporting or investigating a suspected violation of law; or, (B) made in
a complaint or other document that is filed in a lawsuit or other proceeding, if such filing is made under seal so that it is
not made public. Further, an individual who pursues a lawsuit for retaliation by an employer for reporting a suspected
violation of the law may disclose the trade secret to the attorney of the individual and use the trade secret information in
the court proceeding, if the individual (A) files any document containing the trade secret under seal, and (B) does not
disclose the trade secret, except as permitted by court order. Nothing in this Agreement is intended to conflict with the
DTSA or create liability for disclosures of trade secrets that are expressly allowed by such section. Further, nothing in any
agreement the Executive has with the Company shall prohibit or restrict the Executive from making any voluntary disclosure to
any governmental agency or legislative body, or any self-regulatory organization, in each case, without advance notice to the
Company.

 

    5

     

    

 

(e)          
Nondisparagement. The Executive covenants that during and following the Employment Term, the Executive will not disparage
or encourage or induce others to disparage the Company or its subsidiaries and affiliates, together with all of their respective
past and present directors and officers, as well as their respective past and present managers, officers, shareholders, partners,
employees, agents, attorneys, servants and customers and each of their predecessors, successors and assigns (collectively, the
 “Company Entities and Persons”). The term “disparage” includes, without limitation, comments or
statements adversely affecting in any manner (i) the conduct of the business of the Company Entities and Persons, or (ii) the business
reputation of the Company Entities and Persons. Nothing in this Agreement is intended to or shall prevent the Executive from providing,
or limiting testimony in any judicial, administrative or legal process or otherwise as required by law, prevent the Executive from
engaging in truthful testimony pursuant to any proceeding under this Section 6 or Section 7 below or prevent the Executive from
making statements in the course of doing his normal duties for the Company.

 

(f)           
Intellectual Property. The Executive’s written and otherwise tangible work product rendered pursuant to this
Agreement is works for hire, and is the sole property of the Company. The Executive shall retain no rights in such written and
otherwise tangible work product. The Executive hereby assigns to the Company any and all right, title and interest he may have
in any written and otherwise tangible work product which he may invent and assist in inventing, while performing the services pursuant
to this Agreement. The Executive hereby assigns to the Company any interest he may have in any inventions, patents, designs, trade
names, trademarks, service marks or other forms of intellectual property which he may create or assist in the creating in the course
of his provision of services pursuant to this Agreement. The Executive shall disclose to the Company all art which he has invented
in the course of rendering services pursuant to this Agreement. The Executive shall assist the Company in securing protection of
intellectual property by signing agreements, assignments and other documents.

 

(g)          
Cooperation. The Executive shall provide reasonable cooperation in connection with any action or proceeding (or any
appeal from any action or proceeding) which relates to events during the Executive’s employment hereunder. The Company shall
reimburse the Executive for the Executive’s reasonable travel expenses incurred in connection with the foregoing, in accordance
with the Company’s policies and subject to the delivery of reasonable support for such expenses.

 

(h)          
Blue Pencil. It is the intent and desire of the Executive and the Company that the provisions of this Section 6 be
enforced to the fullest extent permissible under the laws and public policies as applied in each jurisdiction in which enforcement
is sought. If any particular provision of this Section 6 shall be determined to be invalid or unenforceable, such covenant shall
be amended, without any action on the part of either party hereto, to delete therefrom the portion so determined to be invalid
or unenforceable, such deletion to apply only with respect to the operation of such covenant in the particular jurisdiction in
which such adjudication is made.

 

    6

     

    

 

(i)            
Survival. The Executive’s obligations under this Section 6 shall survive the termination of the Employment
Term.

 

(j)            
Restrictions Reasonable. The Executive confirms that all restrictions and covenants in this Section 6 (the “Restrictive
Covenants”) are reasonable and valid, and waives all objections to and defenses to the strict enforcement thereof.

 

7.                 
Remedies for Breach of Obligations under Section 6 hereof. The Executive acknowledges that the Company and its subsidiaries
and affiliates will suffer irreparable injury, not readily susceptible of valuation in monetary damages, if the Executive breaches
the Executive’s obligations under Section 6 hereof. Accordingly, Executive agrees that the Company and its subsidiaries and
affiliates will be entitled, in addition to any other available remedies, to obtain injunctive or other equitable relief against
any breach or prospective breach by the Executive of the Executive’s obligations under Section 6 hereof in any Federal or
state court sitting in the State of New Jersey or, at the Company’s election, in any other state in which the Executive maintains
the Executive’s principal residence or the Executive’s principal place of business, without the necessity of showing
actual damages or that money damages would not afford an adequate remedy. The Executive hereby submits to the non-exclusive jurisdiction
of all those courts for the purposes of any actions or proceedings instituted by the Company or its subsidiaries and affiliates
to obtain that injunctive relief, and the Executive agrees that process in any or all of those actions or proceedings may be served
by registered mail, addressed to the last address provided by the Executive to the Company, or in any other manner authorized by
law. Any equitable relief shall be in addition to, and not instead of, legal remedies, monetary damages or other available relief.

 

8.                 
Termination of Employment.

 

(a)          
Termination by the Company for Cause; Voluntary Termination.

 

(i)                
The Company may terminate the Executive’s employment for Cause at any time immediately upon notice. For purposes of
this Agreement, “Cause” means (1) the Executive’s commission of an act of fraud or dishonesty in the course
of his employment hereunder; (2) the Executive’s indictment, conviction or entering of a plea of nolo contendere for a crime
constituting a felony; (3) the Executive’s gross negligence or willful misconduct in connection with his employment hereunder;
(4) the Executive’s willful and continued failure to substantially perform his duties hereunder; (5) the Executive’s
breach of any of the Restrictive Covenants; or (6) a material breach of this Agreement or any other agreement, plan or arrangement
by and between the Executive and the Company or any of its subsidiaries and affiliates or any policy of the Company or any of its
subsidiaries and affiliates by the Executive.

 

(ii)              
The Executive shall have the right to resign at any time by giving the Company 30 days’ notice of the termination
date, subject to the Company’s right, at its election, to reduce the duration of the notice period upon notice to the Executive,
in which case the last day of the reduced notice period shall constitute the date of termination.

 

    7

     

    

 

(iii)             
In the event of any such termination pursuant to this Section 8(a), the Company will have no further liability to the Executive
except for payment of (1) any earned but unpaid base salary, (2) any incurred but unreimbursed business expenses, and (3) any accrued
but unused vacation and sick days that exist as of the date of the Executive’s termination of employment (together, the “Accrued
Benefits”).

 

(b)           Termination
Without Cause or For Good Reason. The Company may terminate the Executive’s employment at any time without Cause or
the Executive may resign at any time for Good Reason (as that term is defined herein) upon 30 days’ advance notice to the
other party (in each case, a “Qualifying Termination”), subject to the Company’s right, at its election,
to reduce the duration of the notice period upon notice to the applicable party, in which case the last day of the reduced notice
period shall constitute the date of termination. In the event of such a Qualifying Termination, the Executive will receive the
Accrued Benefits and, if the Executive (1) executes a commercially reasonable release of any and all claims arising from, or related
to, the Executive’s employment with the Company, which release shall be in substantially the form attached as Exhibit B
hereto (the “Release”), and the applicable revocation period with respect thereto expires within 30 days following
the date of termination; and (2) continues to comply with all restrictive covenants and all other material ongoing obligations
to which he is subject (the “Obligations”), then the Company shall:

 

(i)                
provide the Executive with a lump sum cash payment in an amount equal to 100% of the Executive’s Base Salary then
in effect, which shall be paid within 60 days following the date of termination;

 

(ii)              
if the Executive qualifies for and timely elects continuation coverage under the Consolidated Omnibus Budget Reconciliation
Act of 1985 (“COBRA”), continue to make monthly contributions in respect of the Executive’s coverage under
the Healthcare Plan for 12 months following the date of termination, in each case, in an amount equal to the contribution the Company
would have made if the Executive had continued to be an active employee (assuming the applicable rates in effect as of the date
of the Executive’s termination of employment); provided that, the Company’s obligations under this Section 8(b)(ii)
shall terminate on the earlier of (i) the date on which the Executive enrolls in a group health plan offered by another employer
and (ii) the date on which the Executive is no longer eligible for continuation coverage under COBRA; provided further that, notwithstanding
the foregoing, in the event such Company contributions, may, in the Company’s reasonable view, result in tax or other penalties
on the Company, this provision shall terminate and the parties shall, in good faith, negotiate for a substitute provision that
provides substantially a similar benefit to the Executive but does not result in such tax or other penalties; and

 

(iii)             
cause any then-unvested RSUs and options to purchase Menlo common stock held by the Executive to become fully vested and
exercisable and provide that such options remain exercisable for ninety days following the date of termination (the “Equity
Acceleration”).

 

    8

     

    

  

(c)          
Qualifying Termination in Connection with Change in Control. Notwithstanding anything set forth in Section 8(b),
if a Qualifying Termination occurs within the period that is one year following a Change in Control (as defined in the Menlo 2019
Equity Incentive Plan; provided that, for the avoidance of doubt, the transactions that occurred on and as of the Effective Date
by and between Menlo, Foamix Pharmaceuticals Ltd. and their respective subsidiaries and affiliates shall not constitute a Change
in Control), then the Executive will receive the Accrued Benefits and, if the Executive (1) executes a Release and the applicable
revocation period with respect thereto expires within 55 days following the date of termination and (2) continues to comply with
all Obligations the following will occur:

 

(i)                
the Executive shall be paid a lump sum cash amount equal to 1.5 times the sum of the Executive’s Base Salary then
in effect and the Executive’s Target Bonus for the year of termination, which shall be paid within 60 days following the
date of termination;

 

(ii)              
the Executive shall be paid a lump sum cash amount equal to the Target Bonus for the year of termination multiplied by a
fraction, the numerator of which is the number of days the Executive was employed with the Company during the calendar year in
which the date of termination occurs, and the denominator of which is 365, which shall be paid within 60 days following the date
of termination;

 

(iii)             
if the Executive qualifies for and timely elects continuation coverage under COBRA, the Company will continue to make monthly
contributions in respect of the Executive’s coverage under the Healthcare Plan for 18 months following the date of termination,
in each case, in an amount equal to the contribution the Company would have made if the Executive had continued to be an active
employee (assuming the applicable rates in effect as of the date of the Executive’s termination of employment); provided
that, the Company’s obligations under this Section 8(c)(ii) shall terminate on the earlier of (i) the date on which the
Executive enrolls in a group health plan offered by another employer and (ii) the date on which the Executive is no longer eligible
for continuation coverage under COBRA; provided further that, notwithstanding the foregoing, in the event such Company contributions,
may, in the Company’s reasonable view, result in tax or other penalties on the Company, this provision shall terminate and
the parties shall, in good faith, negotiate for a substitute provision that provides substantially a similar benefit to the Executive
but does not result in such tax or other penalties;

 

(iv)             
the Executive will receive the Equity Acceleration.

 

(d)           Death or Disability. In the event of the Executive’s death or the termination of the Executive’s employment
as a result of the Executive’s disability (as determined by the Company in good faith), the Company will have no further
liability to the Executive except for payment of the Accrued Benefits. For the avoidance of doubt, a termination of the Executive’s
employment pursuant to this Section 8(d) shall not be considered a Qualifying Termination.

  

    9

     

    

 

(e)          
Good Reason. For purposes of this Agreement, “Good Reason” means (i) a material diminution in the Executive’s
Base Salary or Target Bonus (provided that failure to earn a bonus equal to or in excess of the Target Bonus by reason of failure
to achieve applicable performance goals shall not be deemed Good Reason); (ii) a material diminution of the Executive’s
position, responsibilities, duties or authorities from those in effect as of the Effective Date; (iii) any change in reporting
structure such that the Executive is required to report to someone other than the Board; (iv) any material breach by the Company
of its obligations under this Agreement; or (v) a change in the Executive’s primary work location that increases the Executive’s
commute by more than 50 miles. Executive shall provide notice of the existence of the Good Reason condition within 30 days of
the date Executive learns of the condition, and the Company shall have a period of thirty 30 days during which it may remedy the
condition, and in case of full remedy such condition shall not be deemed to constitute Good Reason hereunder.

 

(f)           
Form of Payment for Compliance with Section 409A. Notwithstanding anything in this Agreement to the contrary, to
the extent that the payments and benefits provided pursuant to this Section 8 are determined to be “deferred compensation”
for purposes of Section 409A of the Internal Revenue Code or any successor provision thereto (the “Code”), and
to the extent necessary to avoid accelerated taxation and/or tax penalties under Section 409A of the Code, the payments and benefits
provided pursuant to this Section 8 shall be paid at the same time(s) and in the same form(s) provided in Section 7 of the Previous
Employment Agreement, at all times, in accordance with Section 409A of the Code.

 

9.                 
Certain Tax Treatment

 

(a)          
Golden Parachute Tax. To the extent that the payments and benefits provided under this Agreement and benefits provided
to, or for the benefit of, the Executive under any other plan or agreement of the Company or any of its affiliates (such payments
or benefits are collectively referred to as the “Payments”) would be subject to the excise tax (the “Excise
Tax”) imposed under Section 4999 of the Code, or any similar tax imposed by state or local law, then such payments and
benefits shall be reduced to the extent necessary such that no Payment to be made or benefit to be provided to the Executive shall
be subject to the Excise Tax (such reduced amount is hereinafter referred to as the “Limited Payment Amount”),
but only if such reduction results in a higher after-tax payment to the Executive after taking into account the Excise Tax and
any additional taxes (including federal, state and local income taxes, employment, social security and Medicare taxes and all other
applicable taxes) that the Executive would pay if such Payments were not reduced. The determination of the amount of Payments that
would be required to be reduced to the Limited Payment Amount pursuant to this Agreement and the amount of such Limited Payment
Amount shall be made, at the Company’s expense, by a reputable accounting firm selected by the Company (the “Accounting
Firm”). The Accounting Firm shall provide its determination (the “Determination”), together with detailed
supporting calculations and documentation to the Company and Executive within ten (10) days of the date of termination, if applicable,
or such other time as specified by mutual agreement of the Company and the Executive. The Determination shall be binding, final
and conclusive upon the Company and the Executive, absent manifest error. For purposes of making the calculations required by this
Section 9(a), the Accounting Firm may make reasonable assumptions and approximations concerning applicable taxes and rates, and
rely on reasonable, good faith interpretations concerning the application of the Code, and other applicable legal authority..

 

    10

     

    

  

(b)          
Ordering of Reduction. In the case of a reduction in the Payments pursuant to Section 9(a), the Payments will be
reduced in the following order: (i) payments that are payable in cash that are valued at full value under Treasury Regulation
Section 1.280G-1, Q&A 24(a) will be reduced (if necessary, to zero), with amounts that are payable last reduced first; (ii)
payments and benefits due in respect of any equity valued at full value under Treasury Regulation Section 1.280G-1, Q&A 24(a),
with the highest values reduced first (as such values are determined under Treasury Regulation Section 1.280G-1, Q&A 24) will
next be reduced; (iii) payments that are payable in cash that are valued at less than full value under Treasury Regulation Section
1.280G-1, Q&A 24, with amounts that are payable last reduced first, will next be reduced; (iv) payments and benefits due in
respect of any equity valued at less than full value under Treasury Regulation Section 1.280G-1, Q&A 24, with the highest
values reduced first (as such values are determined under Treasury Regulation Section 1.280G-1, Q&A 24) will next be reduced;
and (v) all other non-cash benefits not otherwise described in clauses (ii) or (iv) will be next reduced pro-rata.

 

10.              
Executive Representations. The Executive represents and warrants (i) that there is no legal restriction and/or contractual
restriction prohibiting him from entering into an employment relationship with the Company, (ii) that by doing so he is not violating
any third party’s rights and (iii) that he knows that the Company is employing him based upon this statement.

 

11.              
Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the
State of New Jersey, without regard to any choice-of-law rules thereof. The parties agree that the sole and exclusive forum for
the adjudication of any disputes arising under this Agreement shall be the New Jersey Superior Court, Somerset County or the United
States District Court for the District of New Jersey. The parties irrevocably agree to submit to the jurisdiction of the said courts
for that purpose and the laying of venue in the said courts for that purpose. The parties further agree that all disputes submitted
to either court shall be tied to the court without a jury and they expressly waive any right to trial by jury of any disputes arising
under this agreement, including all statutory claims under federal, state or local law.

 

12.              
Entire Agreement. This Agreement constitutes and expresses the whole agreement of the parties hereto with reference
to any of the matters or things herein provided for or herein before discussed or mentioned with reference to the Executive’s
employment, and it cancels and replaces any and all prior understandings and agreements between the Executive and the Company,
including the Previous Employment Agreement. All promises, representations, collateral agreements and understandings not expressly
incorporated in this Agreement are hereby superseded by this Agreement.

 

13.              
Tax Withholding. The Company may withhold from any amounts payable under this Agreement all federal, state, city
or other taxes as it is required to withhold pursuant to any applicable law, regulation or ruling. Notwithstanding any other provision
of this Agreement, the Company shall not be obligated to guarantee any particular tax result for the Executive with respect to
any payment provided to the Executive hereunder, and the Executive shall be responsible for any taxes imposed on the Executive
with respect to any such payment.

 

    11

     

    

 

14.              
Counterparts. This Agreement may be executed on separate counterparts, any one of which need not contain signatures
of more than one party, but all of which taken together will constitute one and the same agreement.

 

15.              
Notice. Any notice required or permitted to be given under this Agreement shall be in writing and shall be properly
given if personally delivered, or delivered by email or facsimile, in each case as follows:

 

		If to the Company:
	 	 Menlo Therapeutics Inc.

520 U.S. Highway 22, Suite 204

Bridgewater, NJ 08807

Attention: Head of Human Resources

Telephone: 800.775.7936

Email: ray.steitz@foamix.com

If to the Executive:

Using the information on file in the Company’s
payroll records.

 

16.              
Survival. The representations, warranties and covenants of the Executive contained in this Agreement will survive
any termination of the Executive’s employment with the Company and its subsidiaries and affiliates.

 

17.              
Amendments. No modification, amendment or variation hereof will be of effect or binding upon the parties hereto unless
agreed to in writing by each of them and thereafter such modification, amendment or variation will have the same effect as if it
had originally formed part of this Agreement.

 

18.              
Severability. If any covenant or provision contained herein is determined to be void, invalid or unenforceable in
whole or in part for any reason whatsoever, it will not be deemed to affect or impair the validity or enforceability of any other
covenant or provisions hereof, and such unenforceable covenant or provisions or part thereof will be treated as severable from
the remainder of this Agreement.

 

19.              
Waiver. No waiver by the parties hereto of any breach of any condition, covenant or agreement hereof will constitute
a waiver of such condition, covenant or agreement except in respect of the particular breach giving rise to such waiver.

 

    12

     

    

  

20.              
Section 409A. The intent of the parties is that payments and benefits under this Agreement comply with Section 409A
of the Internal Revenue Code of 1986, as amended (“Section 409A”), to the extent subject thereto, and accordingly,
to the maximum extent permitted, this Agreement shall be interpreted and administered to be in compliance therewith. Notwithstanding
anything contained herein to the contrary, the Executive shall not be considered to have terminated employment with the Company
for purposes of any payments under this Agreement which are subject to Section 409A until the Executive would be considered to
have incurred a “separation from service” from the Company within the meaning of Section 409A. Each amount to be paid
or benefit to be provided under this Agreement shall be construed as a separate identified payment for purposes of Section 409A.
Without limiting the foregoing and notwithstanding anything contained herein to the contrary, to the extent required in order
to avoid accelerated taxation and/or tax penalties under Section 409A, amounts that would otherwise be payable and benefits that
would otherwise be provided pursuant to this Agreement or any other arrangement between the Executive and the Company during the
six-month period immediately following the Executive’s separation from service shall instead be paid on the first business
day after the date that is six months following the Executive’s separation from service (or, if earlier, the Executive’s
date of death). To the extent required to avoid an accelerated or additional tax under Section 409A, amounts reimbursable to the
Executive under this Agreement shall be paid to the Executive on or before the last day of the year following the year in which
the expense was incurred and the amount of expenses eligible for reimbursement (and in kind benefits provided to the Executive)
during one year may not affect amounts reimbursable or provided in any subsequent year. Notwithstanding anything set forth in
Section 8 to the contrary, to the extent necessary to avoid accelerated taxation and/or tax penalties under Section 409A, the
 “Payment Commencement Date” shall be the 60th day following the date of termination. The Company makes no representation
that any or all of the payments described in this Agreement will be exempt from or comply with Section 409A and makes no undertaking
to preclude Section 409A from applying to any such payment.

 

[Signature Page Follows]

 

    13

     

    

 

	 	Yours sincerely,
	 	 
	 	MENLO THERAPEUTICS INC.
	 	 
	 	 
	 	By:	/s/ Rex Bright
	 	Name:	 Rex Bright
	 	Title:	Chairman of the Compensation Committee of the Board of Directors
	 	 
	 	 
	ACKNOWLEDGED AND AGREED:	 
	 	 
	 	 
	/s/ David Domzalski	 
	David Domzalski	 

 

[Signature Page to Agreement]

 

    

     

    

 

Exhibit A

 

Duties and Responsibilities

 

The
Chief Executive Officer has a deep passion for the company’s mission, sets and fulfills strategic vision, oversees all operations
and steers the organization through hands-on executive leadership.

 

The CEO will:

 

		·	Report to the Board of Directors and have responsibility for managing the Company, both internally
and externally.
	 	 	 

		·	Establish rapport and a solid working relationship with the Board.
	 	 	 

		·	Provide the necessary reporting materials and communicate effectively and openly to the Board.
	 	 	 

		·	Provide the vision, leadership, and teamwork necessary to build an organization capable of achieving
its maximum potential.
	 	 	 

		·	Assume full strategic, financial and operational responsibility for continuing the transformation
of the Company from a research phase to a market-driven, successful commercial specialty pharmaceuticals company.
	 	 	 

		·	Build and lead the management team on key strategic business issues and have accountability for
operational planning and successful execution.
	 	 	 

		·	Have full P&L responsibility and accountability while managing existing cash, raising additional
capital as necessary from institutional investors or other sources to build the Company into a high growth entity.
	 	 	 

		·	Strategize, layout, and implement FDA and other regulatory approval pathways along with a strong,
well thought-out product development, clinical, and reimbursement strategy.
	 	 	 

		·	Provide strategic input and leadership on decision making
issues affecting the organization; specifically relating to business development and the evaluation of potential mergers, acquisitions
or partnerships.

 

		·	Continue to grow a robust IP portfolio building upon the current IP and protecting new IP.

 

		·	Assure that the Company has adequate human resources to meet its objectives, while closely managing
the cash burn rate in order to bring the Company to product launch and commercialization.
	 	 	 

		·	Evaluate the operational strategy of the company and ensure that timelines are met to ensure the
Company achieves commercial readiness.
	 	 	 

		·	Lead day-to-day operations by demonstrating a visible presence, an emphasis on effective communications,
superior goal clarity, and organized problem solving.
	 	 	 

		·	Work with the senior management team to align priorities, create a sense of urgency, hold accountable,
work as a cohesive team, and achieve effective results.
	 	 	 

		·	Evaluate industry trends and be proactive in altering products and marketing strategies to enhance
the financial value of the Company.
	 	 	 

		·	Develop rapport with key opinion leaders, clinicians, associations, and the financial community.
	 	 	 

		·	Create and maintain a culture that enables optimal creativity, connectivity, open communication,
accountability, and a sense of urgency.
	 	 	 

		·	Mentor and inspire the organization towards excellence providing support, challenges, and professional
growth for the senior team and extended staff.

 

    

     

    

 

Exhibit B

 

Form of Release

 

In
consideration for the payments set forth in Section 8 of the Employment Agreement, made and entered into as of [●],
by and between Foamix Pharmaceuticals Inc., a New Jersey corporation (the “Company”), and David Domzalski
(the “Executive”), (together, the “Parties”), Executive agrees to the following:

 

(a)                           Executive
represents that Executive has not filed any complaints, charges or lawsuits against the Company with any governmental agency or
any court.

 

(b)                           Executive hereby
forever releases and discharges the Company and its parents, subsidiaries, affiliates, predecessors, successors, and assigns, as
well as each of its past and present officers, directors, employees, agents, attorneys, and stockholders (collectively, the “Company
Released Parties”) from any and all claims, charges, complaints, liens, demands, causes of action, obligations, damages,
and liabilities, known or unknown, suspected or unsuspected, that Executive had, now has, or may hereafter claim
to have against the Company Released Parties arising out of, or relating in any way to, Executive’s employment or other relationship
with, or separation from, the Company, or otherwise relating to the Company Released Parties from the beginning of time to the
Effective Date (as defined below). This release specifically extends to, without limitation, any and all claims or causes of action
for wrongful termination, breach of an express or implied contract, breach of the covenant of good faith and fair dealing, breach
of fiduciary duty, fraud, misrepresentation, defamation, slander, infliction of emotional distress, disability, loss of future
earnings, and any claims under any applicable state, federal, or local statutes and regulations, including, but not limited to,
the Civil Rights Act of 1964, as amended, the Equal Pay Act of 1963, as amended, the Fair Labor Standards Act, as amended, the
Age Discrimination in Employment Act of 1967, as amended, the Americans with Disabilities Act of 1990, as amended, the Rehabilitation
Act of 1973, as amended, the Employee Retirement Income Security Act of 1974, as amended, the Worker Adjustment and Retraining
Notification Act, as amended, Section 806 of the Sarbanes-Oxley Act, the Dodd-Frank Act, the Family and Medical Leave Act, as amended,
any claims arising under the New Jersey Law Against Discrimination, the New Jersey Family Leave Act, the New Jersey Conscientious
Employee Protection Act, the New Jersey Wage Payment Law, the New Jersey Wage and Hour Law, retaliation claims under the New Jersey
Workers’ Compensation Law, the New Jersey Equal Pay Act, the New Jersey Civil Union Act, the New Jersey Smoking Law, all
including any amendments and their respective implementing regulations, and any other federal, state, local, or foreign law (statutory,
regulatory, or otherwise) that may be legally waived and released; provided, however, that this release does not
waive, release or otherwise discharge any claim or cause of action arising from a breach of this agreement or that cannot legally
be waived, including, but not limited to, any claim for unpaid wages, workers’ compensation benefits, unemployment benefits
and any claims for indemnification under applicable law.

 

(c)                           This agreement
shall not prevent Executive from filing a charge with the Equal Employment Opportunity Commission (or similar state or local agency)
or from voluntarily communicating with, or participating in any investigation or proceeding that may be conducted by, any governmental
agency, regulatory authority or self-regulatory organization concerning possible violations of law, including providing documents
or other information in that connection to any governmental agency, regulatory authority or self-regulatory organization, in each
case without notice to the Company or any other Company Released Party.

 

    

     

    

 

(d)                           Executive acknowledges
that (i) the Company has advised Executive of Executive’s right to consult with an attorney of Executive’s own choosing,
to the extent Executive wishes to do so, prior to executing this agreement, (ii) Executive has carefully read and fully understands
all of the provisions of this agreement, (iii) Executive is entering into this agreement, including the releases set forth in this
agreement, knowingly, freely and voluntarily in exchange for good and valuable consideration that is in addition to any consideration
Executive would otherwise be entitled to receive, (iv) the release in this agreement applies to and covers all claims against the
Company and the other company-related released parties, including those under the Age Discrimination in Employment Act of 1967,
as amended (“ADEA”), and its implementing regulations whether or not Executive knows or suspects them to exist
at the present time, and (v) this release does not govern any rights or claims that might arise under the ADEA after the date this
agreement is signed by the Parties.

 

(e)                           CONSIDERATION
AND REVOCATION PERIODS

 

(i)       Executive
acknowledges that Executive has been given at least [twenty-one (21)/forty-five (45)]1 calendar days to consider the
terms of this agreement, although Executive may sign it sooner. Executive agrees that any modifications, material or otherwise,
made to this agreement, does not restart or affect in any manner the original [twenty-one (21)/forty-five (45)]2 calendar
day consideration period, which began to run on the date when the Company provided this agreement to Executive.

 

(ii)       Executive
has seven (7) calendar days from the date on which Executive signs this agreement to revoke consent to the terms of this agreement.
Notice of such revocation must be received within the seven (7) calendar days referenced in the preceding sentence.

 

(iii)       In
the event of such revocation by Executive, this agreement shall be null and void in its entirety and neither Executive nor the
Company shall have any rights or obligations under this agreement.

 

(iv)       Provided
that Executive does not revoke this agreement, this agreement shall become effective on the eighth (8th) calendar day after the
date on which Executive signs it (the “Effective Date”).

 

[Signature Page Follows]

 

 

1
Appropriate review period to be determined at the time of separation.

 

2
Appropriate review period to be determined at the time of separation.

 

    

     

    

  

IN
WITNESS WHEREOF, David Domzalski and Foamix Pharmaceuticals Inc. have executed this agreement as of the first date set forth
below.

 

	FOAMIX PHARMACEUTICALS INC.	 	DAVID DOMZALSKI
	 	 	 
	 	 	 
	By:  	 	 	 
	Name: 	 	 
	Title:  	 	 
	 	 	 
	 	 	 
	Date:	                  	 	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]